Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Higinia Rosa Cardenes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6559-1807; OpenAlex author ID A5005327380. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  2. Dosimetric impact of gastrointestinal air column in radiation treatment of pancreatic cancer. Co-author DOI 10.1259/bjr.20170512↗
  3. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience. Co-author DOI 10.1097/coc.0000000000000115↗
  4. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic ca… Last author DOI 10.1016/j.ijrobp.2014.02.024↗
  5. Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: are noncoplanar beam angles necessary? Last author DOI 10.1007/s12094-012-0998-5↗
  6. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group stu… Co-author DOI 10.1097/coc.0b013e3181e9c103↗
  7. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. Co-author DOI 10.1200/jco.2011.34.8904↗

Trials 1

  1. Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer Principal investigator NCT00243854↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Indra J. Das · 2 shared papers, 2013–2018 · strength 0.16
  2. Patrick Joseph Loehrer · 4 shared papers, 2011–2017 · strength 0.15
  3. Elena Gabriela Chiorean · 3 shared papers, 2011–2017 · strength 0.13
  4. Neil C. Estabrook · 1 shared paper, 2018 · strength 0.11
  5. Muhammad Rizwan Khawaja · 1 shared paper, 2017 · strength 0.07
  6. David S. Chang · 1 shared paper, 2013 · strength 0.05
  7. Romnee S. Clark · 1 shared paper, 2014 · strength 0.03
  8. Safi Shahda · 1 shared paper, 2014 · strength 0.03
  9. Kumaresan Sandrasegaran · 1 shared paper, 2014 · strength 0.03
  10. John M. DeWitt · 1 shared paper, 2014 · strength 0.03
  11. Gabriela Chiorean · 1 shared trial, 2005 · strength 0.03
  12. David F Cella · 1 shared paper, 2011 · strength 0.02
  13. Ramesh K. Ramanathan · 1 shared paper, 2011 · strength 0.02
  14. Steven R. Alberts · 1 shared paper, 2011 · strength 0.02
  15. Christopher H. Crane · 1 shared paper, 2011 · strength 0.02
  16. Al B. Benson · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.